Skip to main content

Latigo Biotherapeutics, Inc.

For the period ended Jun 30, 2026. Filed Sep 3, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Sep 3, 2026

LTGO$13.35+6.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 6. Exhibits

Exhibit number · Description of document · Incorporated by Reference · FiledHerewith
Form · Date · Number
3.1Amended and Restated Certificate of Incorporation.8-K8/10/20263.1
3.2Amended and Restated Bylaws.S-1/A8/03/20263.4
4.1Form of Common Stock Certificate.S-1/A8/03/20264.1
4.2†Amended and Restated Investors’ Rights Agreement, dated January 28, 2025, by and among the Registrant and the investors named therein.S-17/17/20264.2
10.1Form of Indemnification Agreement, between the Registrant and each of its directors and executive officers.S-17/17/202610.1
10.2*Latigo Biotherapeutics, Inc. 2026 Equity Incentive PlanS-88/10/202699.3
10.3*Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise under theLatigo Biotherapeutics, Inc. 2026 Equity Incentive Plan.S-17/17/202610.5
10.4*Latigo Biotherapeutics, Inc. 2026 Employee Stock Purchase Plan.S-88/10/202699.5
10.5*Non-Employee Director Compensation Policy.S-1/A8/03/202610.7
10.6*Latigo Biotherapeutics, Inc. Severance Plan.S-17/17/202610.14
10.7*Executive Employment Agreement, dated July 15, 2026, between the Registrant and Nima Farzan.S-17/17/202610.11
10.8*Executive Employment Agreement, dated July 15, 2026, between the Registrant and Neil Singla, M.D.S-17/17/202610.12
10.9*Executive Employment Agreement, dated July 15, 2026, between the Registrant and Neha Krishnamohan.S-17/17/202610.13
31.1Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.X
31.2Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.X
32.1+Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.X
101.INSInline XBRL Instance DocumentX
101.SCHInline XBRL Taxonomy Extension Schema With embedded Linkbase DocumentsX
104Cover Page Interactive Data File (embedded within the Inline XBRL document)X
  • Indicates a management contract or any compensatory plan, contract or arrangement.

† Certain schedules and exhibits to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K.

  • This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.